



Pressrelease

Lund November 26, 2014

EXINI heart reaches 500 installations in Japan

Fast-paced market penetration for EXINI heart (cardioREPO in Japan) continues thanks to EXINI's partner FUJIFILM RI Pharma Co. Ltd that carries the exclusive rights for Japan. Installations in more than 500 clinics within 5 months bring about a significant change in how physicians analyses heart images in clinical practice.

Concurrently, EXINI's first product on the Japanese market, EXINI bone^{BSI} (BONENAVI) now counts installations in more than 800 clinics throughout Japan.

"I'm very proud of my organization and the successful launch that paved the way for this quick breakthrough. EXINI is a truly competent partner, meticulous in how they handle both our requests and those of our Japanese physicians", comments Morita Toshiya, Vice President and Board Member, FUJIFILM RI Pharma Co. Ltd.

"CardioREPO's installation rate is impressive and surpasses the launch of our first product, BONENAVI (EXINI bone^{BSI}). We're encouraged that we, together with FUJIFILM RI Pharma, will reach our mutual sales target rendering EXINI at least 20 MSEK in added bonus payment during the 5 year agreement term", comments Magnus Aurell, CEO EXINI Diagnostics AB.

About cardioREPO (EXINI heart)

The product cardioREPO is an advanced customization of the diagnostic software system EXINI heart developed for the Japanese market, and providing clinics and specialists with advanced information crucial in managing patients suffering from suspected or known ischaemic heart conditions (e.g. heart attacks or angina).

About BONENAVI (EXINI bone^{BSI})

BONENAVI is an advanced customization of the diagnostic software system EXINI bone^{BSI} developed for the Japanese market. Its feature capacity to calculate BSI-value (Bone Scan Index) provides clinics and specialists with unique industry leading capacity for prognosis, diagnosis and treatment response in managing patients suffering from advanced breast- or prostate cancer.

For more information, please contact:

Magnus Aurell, CEO

Phone: +46 46-286 54 25

E-mail: magnus.aurell@exini.com

About EXINI Diagnostics AB (publ)

EXINI Diagnostics AB (publ) offers advanced solutions for medical decision support to hospitals worldwide. The system is based on advanced image analysis by artificial intelligence and can make its own interpretation of medical images and provide diagnostic suggestions. In this way the system is used as a decision support for the diagnosing doctor. EXINI is working with products for the diagnosis of some of the most frequent endemic diseases such as cancer, coronary heart disease, dementia and Parkinson's disease. EXINI is listed on the stock market Nasdaq First North and has about 600 shareholders. Consensus acts as Certified Adviser.